Survival Advantage of Coagulation Factor XI–Deficient Mice during Peritoneal Sepsis

Citations Over TimeTop 14% of 2008 papers

Abstract

Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections.

Related Papers

• → The problem with coagulopathy …(2022)1 cited
• → Leukocyte deformability is a novel biomarker to reflect sepsis‐induced disseminated intravascular coagulation(2014)7 cited
• Consumptive coagulopathy in severe preeclampsia.(1976)
• → Subtotal Splenic Embolization is a Safe and Effective Treatment for Isolated Splenic Vascular Tumors Associated With Consumptive Coagulopathy(2011)3 cited
• → Hemostatic Strategies in Trauma(2021)1 cited